DYAZIDE is a Oral Capsule in the Human Prescription Drug category. It is labeled and distributed by Glaxosmithkline Llc. The primary component is Hydrochlorothiazide; Triamterene.
| Product ID | 0007-3650_20d05ffc-42d0-4847-ba0e-b6f7ee1c7b94 |
| NDC | 0007-3650 |
| Product Type | Human Prescription Drug |
| Proprietary Name | DYAZIDE |
| Generic Name | Hydrochlorothiazide And Triamterene |
| Dosage Form | Capsule |
| Route of Administration | ORAL |
| Marketing Start Date | 1994-03-30 |
| Marketing Category | NDA / NDA |
| Application Number | NDA016042 |
| Labeler Name | GlaxoSmithKline LLC |
| Substance Name | HYDROCHLOROTHIAZIDE; TRIAMTERENE |
| Active Ingredient Strength | 25 mg/1; mg/1 |
| Pharm Classes | Increased Diuresis [PE],Thiazide Diuretic [EPC],Thiazides [CS],Decreased Renal K+ Excretion [PE],Increased Diuresis [PE],Potassium-sparing Diuretic [EPC] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2021-12-31 |
| Marketing Start Date | 1994-03-30 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | NDA |
| Application Number | NDA016042 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 1994-03-30 |
| Marketing Category | NDA |
| Application Number | NDA016042 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | EA |
| Marketing Start Date | 1994-03-30 |
| Marketing End Date | 2020-04-29 |
| Ingredient | Strength |
|---|---|
| HYDROCHLOROTHIAZIDE | 25 mg/1 |
| SPL SET ID: | f6eba4b6-9cd0-4c86-46a8-05a202641c89 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |
| NDC | Brand Name | Generic Name |
|---|---|---|
| 0007-3650 | DYAZIDE | hydrochlorothiazide and triamterene |
| 55154-4510 | DYAZIDE | hydrochlorothiazide and triamterene |
| 65084-135 | DYAZIDE | hydrochlorothiazide and triamterene |